Evidence map›Paper›PMID 40599392›Full record

ReviewFrontiers in dementia2025

Evidence that cholinergic mechanisms contribute to hyperexcitability at early stages in Alzheimer's disease.

Helen E Scharfman, Korey Kam, Áine M Duffy, John J LaFrancois, Paige Leary, Elissavet Chartampila, Stephen D Ginsberg, Christos Panagiotis Lisgaras

Abstract readReview
In one paragraph

Review in Frontiers in dementia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A lifespan staging model of basal forebrain cholinergic vulnerability.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Helen E ScharfmanCenter for Dementia Research, The Nathan Kline Institute of Psychiatric Research, Orangeburg, NY, United States.
Korey KamCenter for Dementia Research, The Nathan Kline Institute of Psychiatric Research, Orangeburg, NY, United States.
Áine M DuffyCenter for Dementia Research, The Nathan Kline Institute of Psychiatric Research, Orangeburg, NY, United States.
John J LaFrancoisCenter for Dementia Research, The Nathan Kline Institute of Psychiatric Research, Orangeburg, NY, United States.
Paige LearyCenter for Dementia Research, The Nathan Kline Institute of Psychiatric Research, Orangeburg, NY, United States.
Elissavet ChartampilaCenter for Dementia Research, The Nathan Kline Institute of Psychiatric Research, Orangeburg, NY, United States.
Stephen D GinsbergCenter for Dementia Research, The Nathan Kline Institute of Psychiatric Research, Orangeburg, NY, United States.
Christos Panagiotis LisgarasCenter for Dementia Research, The Nathan Kline Institute of Psychiatric Research, Orangeburg, NY, United States.

Funding

Impact of sex differences on the trajectory of interactome dysfunctions across the AD spectrumR01AG074004 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, GINSBERG, STEPHEN D · 2021 to 2025
$6.0M
Selective interactome vulnerability across the Alzheimer’s disease spectrumR01AG072599 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI GABRIELA CHIOSIS, STEPHEN D GINSBERG · 2023 to 2026
$5.4M
Hyperexcitability in Alzheimer's DiseaseRF1AG055328 · NIA · NATHAN S. KLINE INSTITUTE FOR PSYCH RES · PI Helen E Scharfman · 2024 to 2026
$2.0M
A chemical chaperomics platform for ADR56AG061869 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2018 to 2019
$1.8M
Selective interactome vulnerability across the Alzheimer’s disease spectrumR56AG072599 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, GINSBERG, STEPHEN D · 2021 to 2021
$1.2M
NIA NIH HHS R01 AG072599NIA NIH HHS R01 AG074004NIA NIH HHS R56 AG061869NIA NIH HHS R56 AG072599NIA NIH HHS RF1 AG055328
6 · The paper itself

Abstract

A long-standing theory for Alzheimer's disease (AD) has been that deterioration of synapses and depressed neuronal activity is a major contributing factor. We review the increasing evidence, in humans and in mouse models, that show that there is often neuronal hyperactivity at early stages rather than decreased activity. We discuss studies in mouse models showing that hyperexcitability can occur long before plaque deposition and memory impairment. In mouse models, a generator of the hyperactivity appears to be the dentate gyrus. We present evidence, based on mouse models, that inhibition of muscarinic cholinergic receptors or medial septal cholinergic neurons can prevent hyperactivity. Therefore, we hypothesize the novel idea that cholinergic neurons are overly active early in the disease, not depressed. In particular we suggest the medial septal cholinergic neurons are overly active and contribute to hyperexcitability. We further hypothesize that the high activity of cholinergic neurons at early ages ultimately leads to their decline in function later in the disease. We review the effects of a prenatal diet that increases choline, the precursor to acetylcholine and modulator of many other functions. In mouse models of AD, maternal choline supplementation (MCS) reduces medial septal cholinergic pathology, amyloid accumulation and hyperexcitability, especially in the dentate gyrus, and improves cognition.

Indexed as

amyloid βcholinergicdown syndromememorymouse modelmuscarinicTg2576Ts65Dn

Identifiers

PMID40599392
PMCPMC12209278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.